CervoMed Inc.
CRVO
$4.20
-$0.04-0.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.60% | -83.37% | -46.56% | -18.31% | -13.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.60% | -83.37% | -46.56% | -18.31% | -13.19% |
| Cost of Revenue | -17.73% | 17.86% | 35.42% | 71.90% | 148.18% |
| Gross Profit | -18.21% | -79.51% | -593.19% | -525.33% | -1,249.95% |
| SG&A Expenses | 8.37% | 5.22% | 30.01% | 11.97% | 9.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.30% | 14.05% | 33.26% | 46.10% | 89.15% |
| Operating Income | -15.06% | -49.07% | -120.90% | -104.36% | -191.91% |
| Income Before Tax | -20.60% | -62.55% | -170.12% | -94.65% | -183.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.60% | -62.55% | -170.12% | -94.65% | -183.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.60% | -62.55% | -170.12% | -94.65% | -183.86% |
| EBIT | -15.06% | -49.07% | -120.90% | -104.36% | -191.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.47% | -52.89% | -162.66% | -38.01% | -104.38% |
| Normalized Basic EPS | -13.46% | -52.87% | -162.62% | -38.01% | -104.37% |
| EPS Diluted | -13.47% | -52.89% | -162.66% | -38.01% | -104.38% |
| Normalized Diluted EPS | -13.46% | -52.87% | -162.62% | -38.01% | -104.37% |
| Average Basic Shares Outstanding | 6.29% | 6.32% | 2.85% | 41.04% | 38.86% |
| Average Diluted Shares Outstanding | 6.29% | 6.32% | 2.85% | 41.04% | 38.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |